FMTX News and Press, Forma Therapeutics Holdings Inc. From 11/12/21

Forma Therapeutics (NASDAQ:FMTX): Q3 GAAP EPS of -$0.91 beats by $0.05. Cash, cash equivalents and marketable securities were $531.8M as of Sept. 30, 2021 Press Release For further details see: Forma Therapeutics EPS beats by $0.05

Significant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers Etavopivat Phase 1 open label extension enrollment in sickle cell disease (SCD) complete, updated results to be presented at American Society of Hematology (ASH) Ann...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release third quarter 2021 financial results Friday, Nov...

Two oral presentations on etavopivat include data from Forma’s Phase 1 open label extension trial in sickle cell disease demonstrating a favorable tolerability profile consistent with previously-reported results Additional data supports improvement in markers of red blo...

Initial eight patients treated in ongoing first-in-human, open-label, dose-finding trial of CBP/p300 inhibitor in late-line mCRPC patients Adaptive trial design intended to efficiently explore safe and efficacious doses of FT-7051 First evaluable patient completing mor...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

The following slide deck was published by Forma Therapeutics Holdings, Inc. in conjunction with this event. For further details see: Forma Therapeutics (FMTX) Investor Presentation - Slideshow

Lone Pine Capital’s 13F portfolio value increased from $27.53B to $31.66B. The number of positions decreased from 38 to 36. They added Moderna, RH, and Twitter and increased Square and ServiceNow. Also, they dropped Mercadolibre, Netflix, Atlassian, Bilibili, and Snowflake. ...

Forma Therapeutics Holdings, Inc. (FMTX) Q2 2021 Results Conference Call August 13, 2021 08:00 AM ET Company Participants Mario Corso - Senior Director-Investor Relations Frank Lee - President & Chief Executive Officer Pat Kelly - Chief Medical Officer Dave Cook - Chief Scientific Officer...

Significant progress achieved with pipeline focused on rare hematologic diseases and cancers Positive Phase 1 results in patients with sickle cell disease (SCD) presented at European Hematology Association (EHA) Virtual Congress supporting etavopivat’s potential to sign...